Full-Time

Regional Sales Director

Health Information Technology Sales

Updated on 8/1/2026

Solventum

Solventum

10,001+ employees

Global healthcare company: wound care, dental

Compensation Overview

$230.4k - $316.8k/yr

+ Variable incentive pay

No H1B Sponsorship

Orlando, FL, USA + 19 more

More locations: Louisville, KY, USA | Nashville, TN, USA | Morrisville, NC, USA | Pompano Beach, FL, USA | Tampa, FL, USA | Memphis, TN, USA | Greenville, SC, USA | Georgia, USA | Louisville, TN, USA | Tallahassee, FL, USA | Charlotte, NC, USA | Gainesville, FL, USA | Fort Myers, FL, USA | Pensacola, FL, USA | Hebron, KY, USA | Baton Rouge, LA, USA | Chattanooga, TN, USA | Jacksonville, FL, USA | Louisiana, USA

Remote

Remote within the Southeast region of the United States; relocation assistance may be authorized. Travel may include up to 50% domestically, with on-site onboarding for new hires.

Category
Sales & Account Management (1)
Required Skills
Forecasting

Get referred to Solventum

See people who can refer or advise you

Requirements
  • A Bachelor's degree or higher and seven years of experience in healthcare revenue cycle, health information technology, and/or consulting services in a private, public, government, or military environment.
  • A high school diploma or GED and fourteen years of experience in healthcare revenue cycle, health information technology, and/or consulting services in a private, public, government, or military environment.
Responsibilities
  • Lead and manage a team of Account Executives, Account Managers, and Healthcare Solution Executives focused on delivering health information technology solutions to an assigned territory of health systems and hospitals in the Southeast United States.
  • Develop and manage sales strategies, activities, costs, operations, and forecast data to determine regional sales team progress toward goals and objectives, territory metrics, and quota analysis for ongoing growth and retention.
  • Implement and drive best practices throughout the sales team to ensure consistent, high-quality, repeatable performance, including the continuing evolution of the company sales process and performance management goals.
  • Position value and benefits with vice president and C-level decision-makers, build sustained relationships, fully negotiate contracts, and close business within the assigned region.
  • Execute business-unit strategies, plans, and programs, both short- and long-range, to ensure profitable sales growth, retention, and expansion.
Desired Qualifications
  • A Master of Business Administration degree or similar Master's degree.
  • Proven leadership, organization, and planning ability.
  • Ability to communicate effectively and clearly with upward and downward audiences.
  • Strong relationship, consultation, and interpersonal skills.
  • Demonstrable experience managing a territory and delivering complex, high-dollar technology solutions across multiple departments in regional and large hospital systems exceeding $14 million annually.
  • Proven ability to coach and assist in developing others, creating success through leadership.
  • Proven ability to delegate effectively.
  • Proven ability to facilitate growth by sponsoring and championing new products, programs, and ideas through encouraging innovation.
  • Work/life balance skills, including the ability to recognize and manage personal signs of stress.
  • Experience designing and developing sales training.
  • Initiative, innovation, continual learning, and personal development.
  • A client-centric style and respect among clients and hospital leadership across the client base.
  • An energetic self-starter with a strong sense of urgency.
  • An action-oriented and results-driven approach.
  • A strong hands-on and disciplined work ethic.
  • A fast pace and commitment to raising personal achievement standards.

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Maplewood, Minnesota

Founded

2023

Get referred to Solventum

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • MedSurg revenue rose 5.2% in Q4 2025, with 3.5% organic growth despite divestitures, showing strong execution[1].
  • Health IT suite includes coding automation eliminating revenue cycle waste and supporting value-based care[4].
  • Dental portfolio offers digitally enabled orthodontic workflows with aligners and bonding agents for disease prevention[4].

What critics are saying

  • AI-native rivals will displace HCIT tools within 12 months, eroding 16% of sales via faster automation[1].
  • EU AI Act enforcement may trigger mandatory recalls of Fluency Align in 2027, costing $150M+ and losing hospital contracts[1].
  • Acera Surgical acquisition may fail margin targets due to 3M carryover costs, dropping EPS below $6.40 guidance in 2026[1].

What makes Solventum unique

  • Solventum spun from 3M on April 1, 2024, focusing on wound care, dental, health IT, and purification[1].
  • The company opened a $200M Eagan Innovation Hub accelerating 20+ new product launches in wound care and digital health[2].
  • Solventum holds over 7,300 patents inherited from 3M, reinforcing its strength in advanced material science and healthcare innovation[4].

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

8%
Simply Wall St
Apr 5th, 2026
Solventum opens $200M Innovation Hub as CAO prepares to retire

Solventum Corporation has opened a $200 million Innovation Hub in Eagan, Minnesota, housing over 1,800 employees and supported by approximately $13 million in state business development funding. The facility focuses on research and development in healthcare innovation, particularly advanced wound care, sterilisation and digital health. The opening coincides with Chief Accounting Officer Mary Wilcox announcing her retirement, effective once a successor is appointed. Wilcox informed the company of her intention on 20 March 2026. The Innovation Hub supports Solventum's emphasis on new product development following its separation from 3M. However, analysts note that near-term execution risks around ERP implementation and supply chain transition remain key factors for investors to monitor.

Yahoo Finance
Mar 1st, 2026
Solventum sells Purification unit, buys Acera Surgical, launches $1B buyback in first year post-3M spin

Solventum reported fourth-quarter sales of $2.0 billion, with organic growth of 3.5% year-over-year, though reported revenue declined 3.7% due to its Purification & Filtration divestiture and the Acera acquisition. Non-GAAP earnings per share reached $1.57, whilst adjusted operating margin was 19.9%. Gross margin fell 230 basis points to 53.5%, with roughly 150 basis points attributed to one-time separation costs from 3M. For 2026, the company guided organic sales growth of 2%–3%, operating margin of 21%–21.5%, and EPS of $6.40–$6.60. Management expects free cash flow around $200 million, or roughly $1 billion excluding separation and divestiture costs. The company closed its acquisition of Acera Surgical to enter the synthetic tissue market and launched a $1 billion share buyback programme. Solventum aims to exit approximately 90% of transitional service agreements with 3M by year-end 2026.

Yahoo Finance
Feb 26th, 2026
Solventum beats quarterly estimates as surgical product demand drives $2B revenue

Solventum, a Minnesota-based medical device maker, beat Wall Street estimates for the fourth quarter, driven by strong demand for wound care and sterilisation products. Revenue reached $2 billion, surpassing analysts' expectations of $1.96 billion, whilst adjusted earnings per share came in at $1.57 versus estimates of $1.50. The company's MedSurg business, which accounts for over half of total revenue, saw sales rise 5.2% year-on-year to $1.24 billion. Solventum forecast 2026 adjusted profit of $6.40 to $6.60 per share, above Wall Street expectations of $6.34. The company is acquiring Acera Surgical for up to $850 million to expand its wound care portfolio and has launched a four-year programme expected to deliver $500 million in annual savings.

Yahoo Finance
Feb 26th, 2026
Solventum Q4 earnings beat expectations with $2B revenue, projects $6.40-$6.60 per share for 2025

Solventum reported fourth-quarter net income of $63 million, or $1.57 per share on an adjusted basis, exceeding Wall Street expectations of $1.50 per share. The Maplewood, Minnesota-based healthcare company posted revenue of $2 billion, surpassing analyst forecasts of $1.97 billion. For the full year, Solventum reported profit of $1.56 billion, or $8.88 per share, with revenue of $8.32 billion. The company expects full-year earnings between $6.40 and $6.60 per share.

PR Newswire
Feb 26th, 2026
Solventum reports Q4 2025 results with 3.5% organic sales growth, sets 2026 guidance

Solventum reported fourth quarter 2025 results with sales of $2 billion, down 3.7% on a reported basis but up 3.5% organically. GAAP diluted earnings per share were $0.36, whilst adjusted diluted earnings per share reached $1.57. Operating cash flow totalled $96 million, with free cash flow of $33 million. The healthcare company's organic sales growth was driven by its Infection Prevention and Surgical Solutions business within MedSurg and Dental Solutions. Full-year 2025 results exceeded expectations for both sales and earnings per share. For 2026, Solventum projects organic sales growth of 2.0% to 3.0%, adjusted earnings per share of $6.40 to $6.60, and free cash flow of approximately $200 million. The company, which spun off from 3M, continues its transformation journey.